Skip to content

Secondary Prophylaxis After Variceal Bleeding in Non-Responders

Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00450164
Acronym
KT-2000
Enrollment
50
Registered
2007-03-21
Start date
2000-11-30
Completion date
2004-06-30
Last updated
2007-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Hemorrhage, Portal Hypertension, Cirrhosis

Keywords

Variceal bleeding, Secondary profilaxis, Hemodynamic, Portal hypertension

Brief summary

Controlled and randomized study comparing combined treatment (nadolol and endoscopic ligation) versus nadolol associated with isosorbide mononitrate or prazosin according to hemodynamic response, in the prevention of esofagic verices rebleeding.

Detailed description

The present is a prospective, randomized, open label study, in parallel groups, in which the patients with hemorrhage caused by esofagic varices will be randomized in two groups of treatment, after control of acute hemorrhage. All the patients included will receive standard medical treatment with beta - blockers and endoscopic ligation of the esofagic varices. The control group will be constituted by the patients assigned to receive endoscopic ligation and nadolol (N). The experimental group will be constituted by patients assigned to receive treatment according to the hemodynamic response. All patients included in the experimental group will receive pharmacologic treatment with nadolol combined with Isosorbide Mononitrate (MNI) or Prazosin (PZ). In both groups it will practice a basal hepatic hemodynamic study in the 4th-5th day after their admitance (after achieve hemodynamic stability for at least 48 h and with hemorrhage controlled) and a second control hepatic hemodynamic study 3-4 weeks after the beginning of the pharmacologic treatment, once adjusted doses. In the experimental group, the responders to N + MNI will keep on this treatment, but nonrespondent in the hemodynamic study will switch treatment to N + PZ and a third hepatic hemodynamic study will be performed 3 to 4 weeks after the dosage adjustement. The randomization will be stratified according to the degree of hepatic failure measured by Child-Pugh classification (classes A and B versus C) The design is random to avoid bias in the selection of the patients.

Interventions

PROCEDUREesofagic varices ligation
DRUGPrazosin

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Any Patient with endoscopically assessed Variceal Bleeding (esofagic and gastric) * Cirrhosis * Patient agreement to be included in the study onsentiment signed

Exclusion criteria

* Any associated comorbidity with life expectancy lesser than 6 months * Patient refusement to be included in the study. * Pregnancy * Failure to control acute bleeding * Previous prophylaxis treatment

Design outcomes

Primary

MeasureTime frame
Compared efficacy (at least 6 moths of follow-up)

Secondary

MeasureTime frame
Mortallity
Rebleeding

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026